NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/07/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,659.74 mln
Float32.26 mln
Earnings Date05/06/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-1.59
Likely manipulated
1-Year Forecast
94.11
Exceptional upside
Relative Strength
78
/ 100
Strongly outperforming
Debt / Equity
0.21
Very low leverage
ROE
-21.04
Deeply negative
Business Description
Tarsus Pharmaceuticals is a US-based company that develops and sells medicines for eye conditions and infectious diseases. Its main product, XDEMVY, treats a common eyelid condition caused by microscopic mites, and is sold through pharmacies, clinics, hospitals, and government health programs. The company is also advancing several pipeline treatments, including therapies for eye redness, Lyme disease prevention, and malaria reduction, all built around the same core ingredient. Founded in 2016 and based in Irvine, California, Tarsus holds a partnership with a Chinese pharmaceutical firm to bring its lead treatment to patients in China.
